Trials / Completed
CompletedNCT02764554
Post-Marketing Surveillance of Lenvima in Korean Patients
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 132 (actual)
- Sponsor
- Eisai Korea Inc. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this post-marketing surveillance (PMS) is to observe the safety profile of Lenvima (lenvatinib) in normal clinical practice setting.
Conditions
Timeline
- Start date
- 2016-11-10
- Primary completion
- 2021-09-29
- Completion
- 2021-09-29
- First posted
- 2016-05-06
- Last updated
- 2021-10-07
Locations
32 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02764554. Inclusion in this directory is not an endorsement.